Asterias Biotherapeutics Company Profile (NYSEMKT:AST)

About Asterias Biotherapeutics (NYSEMKT:AST)

Asterias Biotherapeutics logoAsterias Biotherapeutics, Inc. is a biotechnology company. The Company is engaged in developing and commercializing therapies in the fields of cell therapy and regenerative medicine. The Company has over two technology platforms. The first is an immunotherapy platform to teach cancer patients' immune systems to attack their tumors. The second is pluripotent stem cell platform. Pluripotent cells are a type of stem cell capable of becoming all of the cell types in the human body. From its immunotherapy platform, the Company is developing over two programs. AST-VAC1 (telomerase loaded, autologous dendritic cells), which allows patient's own cells to recognize and fight cancer cells in acute myelogenous leukemia (AML). Together with Cancer Research United Kingdom (CRUK), it is developing AST-VAC2 (telomerase loaded, -allogeneic dendritic cells), -derived from pluripotent stem cells. From its pluripotent stem cell platform, it is developing AST-OPC1, oligodendrocyte progenitor cells.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: N/A
  • Sub-Industry: N/A
  • Symbol: NYSEMKT:AST
  • CUSIP: N/A
  • Web: N/A
Capitalization:
  • Market Cap: $165.03 million
  • Outstanding Shares: 49,263,000
Average Prices:
  • 50 Day Moving Avg: $3.26
  • 200 Day Moving Avg: $3.87
  • 52 Week Range: $2.30 - $5.80
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -4.41
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $7.37 million
  • Price / Sales: 22.39
  • Book Value: $0.91 per share
  • Price / Book: 3.68
Profitability:
  • EBIDTA: ($28,300,000.00)
Misc:
  • Average Volume: 184,392 shs.
  • Beta: 1.58
  • Short Ratio: 10.81
 

Frequently Asked Questions for Asterias Biotherapeutics (NYSEMKT:AST)

What is Asterias Biotherapeutics' stock symbol?

Asterias Biotherapeutics trades on the New York Stock Exchange (NYSE)MKT under the ticker symbol "AST."

How were Asterias Biotherapeutics' earnings last quarter?

Asterias Biotherapeutics Inc (NYSEMKT:AST) issued its quarterly earnings results on Monday, August, 15th. The company reported ($0.12) earnings per share for the quarter, topping the consensus estimate of ($0.19) by $0.07. The business earned $1.53 million during the quarter, compared to analyst estimates of $1.14 million. View Asterias Biotherapeutics' Earnings History.

Where is Asterias Biotherapeutics' stock going? Where will Asterias Biotherapeutics' stock price be in 2017?

2 analysts have issued 1-year price targets for Asterias Biotherapeutics' stock. Their predictions range from $10.00 to $10.00. On average, they expect Asterias Biotherapeutics' share price to reach $10.00 in the next year. View Analyst Ratings for Asterias Biotherapeutics.

What are analysts saying about Asterias Biotherapeutics stock?

Here are some recent quotes from research analysts about Asterias Biotherapeutics stock:

  • 1. According to Zacks Investment Research, "Asterias Biotherapeutics, Inc. is a biotechnology company. It is focused on the field of regenerative medicine. The Company's technologies center on stem cells capable of becoming all of the cell types in the human body, a property called pluripotency. It develops therapies based on pluripotent stem cells to treat diseases or injuries in a variety of medical fields, with an initial focus on the therapeutic areas of neurology and oncology. Asterias Biotherapeutics, Inc. is based in Menlo Park, California. " (3/21/2017)
  • 2. FBR & Co analysts commented, "We are transferring coverage of Asterias Biotherapeutics, Inc. (AST) and maintaining our Outperform rating, but we are lowering our price target to $6 (from $10) to reflect a more conservative view. AST is developing therapies in an area of immense promise that can change the practice of medicine. However, the emerging field of regenerative medicine using stem cell therapy is accompanied by increased regulatory and clinical risk. The company’s lead program (AST-OPC1) is a pluripotent stem cell platform, a cell line derived from embryonic stem cells. Pluripotent stem cells are “master cells” and have the potential to differentiate into any cell type, as well as reproduce indefinitely. AST’s pluripotent stem cells, AST-OPC1, are differentiated into oligodendrocyte progenitor cells, which are glial cells in the central nervous system. AST-OPC1 is being developed for spinal cord injuries (SCIs) and is in a Phase I/IIa trial testing higher doses for safety and efficacy. There is no cure or effective therapy approved for SCI that can rehabilitate patients." (3/7/2017)

Who are some of Asterias Biotherapeutics' key competitors?

How do I buy Asterias Biotherapeutics stock?

Shares of Asterias Biotherapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Asterias Biotherapeutics stock cost?

One share of Asterias Biotherapeutics stock can currently be purchased for approximately $3.35.

Analyst Ratings

Consensus Ratings for Asterias Biotherapeutics (NYSEMKT:AST) (?)
Ratings Breakdown: 2 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $10.00

Analysts' Ratings History for Asterias Biotherapeutics (NYSEMKT:AST)
Show:
DateFirmActionRatingPrice TargetDetails
3/7/2017FBR & CoBoost Price TargetOutperform$6.00 -> $10.00View Rating Details
9/11/2016HC WainwrightReiterated RatingBuy$10.00View Rating Details
5/23/2016Chardan CapitalInitiated CoverageBuy$5.50View Rating Details
5/17/2016Rodman & RenshawReiterated RatingBuy$10.00View Rating Details
8/11/2015MLV & Co.Reiterated RatingBuy$9.00View Rating Details
(Data available from 5/25/2015 forward)

Earnings

Earnings History for Asterias Biotherapeutics (NYSEMKT:AST)
Earnings by Quarter for Asterias Biotherapeutics (NYSEMKT:AST)
Earnings History by Quarter for Asterias Biotherapeutics (NYSEMKT:AST)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/14/2016Q316($0.17)($0.24)$1.50 million$2.10 millionViewN/AView Earnings Details
8/15/2016Q216($0.19)($0.12)$1.14 million$1.53 millionViewListenView Earnings Details
5/16/2016Q116($0.14)($0.27)$1.60 millionViewListenView Earnings Details
3/29/2016Q415($0.13)($0.13)$1.07 millionViewListenView Earnings Details
11/9/2015Q315($0.11)($0.06)$1.40 millionViewN/AView Earnings Details
8/10/2015Q215($0.11)($0.10)ViewListenView Earnings Details
5/7/2015($0.13)($0.14)ViewN/AView Earnings Details
3/10/2015($0.13)($0.11)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Asterias Biotherapeutics (NYSEMKT:AST)
Current Year EPS Consensus Estimate: $-0.68 EPS
Next Year EPS Consensus Estimate: $-0.76 EPS

Dividends

Dividend History for Asterias Biotherapeutics (NYSEMKT:AST)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Asterias Biotherapeutics (NYSEMKT:AST)
Insider Trades by Quarter for Asterias Biotherapeutics (NYSEMKT:AST)
Institutional Ownership by Quarter for Asterias Biotherapeutics (NYSEMKT:AST)
Insider Trades by Quarter for Asterias Biotherapeutics (NYSEMKT:AST)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
1/9/2017Edward WirthInsiderSell3,415$4.60$15,709.00View SEC Filing  
1/9/2017Katharine E SpinkCOOSell4,781$4.60$21,992.60View SEC Filing  
10/6/2016Edward WirthInsiderSell3,415$4.12$14,069.80View SEC Filing  
10/6/2016Katharine E. SpinkCOOSell4,781$4.11$19,649.91View SEC Filing  
9/9/2016Edward WirthInsiderSell14,760$3.52$51,955.20View SEC Filing  
9/9/2016Katharine E. SpinkCOOSell19,336$3.52$68,062.72View SEC Filing  
6/30/2016Stephen Lahue CarttCEOBuy10,000$2.40$24,000.00View SEC Filing  
6/29/2016Richard T LebuhnDirectorBuy5,000$2.38$11,900.00View SEC Filing  
6/10/2016Stephen Lahue CarttCEOBuy50,000$2.93$146,500.00View SEC Filing  
6/9/2016Alfred D KingsleyDirectorBuy4,000$2.93$11,720.00View SEC Filing  
5/13/2016Natale S RicciardiDirectorBuy14,706$3.39$49,853.34View SEC Filing  
9/15/2015Edward WirthinsiderSell2,880$6.00$17,280.00View SEC Filing  
9/15/2015Katharine E. SpinkCOOSell3,760$6.00$22,560.00View SEC Filing  
6/25/2015Andrew ArnoDirectorBuy5,000$4.32$21,600.00View SEC Filing  
2/9/2015Pedro LichtingerCEOBuy128,205$3.90$499,999.50View SEC Filing  
10/1/2014Scarsdale Equities LlcMajor ShareholderBuy60,000$5.93$355,800.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Asterias Biotherapeutics (NYSEMKT:AST)
Latest Headlines for Asterias Biotherapeutics (NYSEMKT:AST)
Source:
DateHeadline
finance.yahoo.com logoAsterias Biotherapeutics Announces Top Leadership Transition
finance.yahoo.com - May 24 at 9:29 AM
prnewswire.com logoAsterias Biotherapeutics Reports First Quarter Financial Results and Recent Development Progress - PR Newswire (press release)
www.prnewswire.com - May 12 at 4:16 PM
reuters.com logoBRIEF-Asterias Biotherapeutics announced new positive serial magnetic resonance imaging data
www.reuters.com - May 11 at 4:06 PM
finance.yahoo.com logoNew MRI Data from Asterias' Ongoing SCiStar Clinical Study Indicates AST-OPC1 Cells Prevent Formation of Damaging Lesion Cavities in Patients Suffering Severe Spinal Cord Injury
finance.yahoo.com - May 11 at 4:06 PM
finance.yahoo.com logoAsterias Biotherapeutics Reports First Quarter Financial Results and Recent Development Progress
finance.yahoo.com - May 11 at 4:06 PM
prnewswire.com logoAsterias Biotherapeutics to Report First Quarter Results on May 11 ... - PR Newswire (press release)
www.prnewswire.com - May 4 at 3:46 PM
finance.yahoo.com logoAsterias Biotherapeutics to Report First Quarter Results on May 11, 2017
finance.yahoo.com - May 4 at 3:46 PM
finance.yahoo.com logoPresidential Symposium at the American Society of Gene and Cell Therapy (ASGCT) 20th Annual Meeting Will Feature Presentation on Asterias' AST-OPC1 for Spinal Cord Injury
finance.yahoo.com - May 3 at 10:35 AM
seekingalpha.com logoBioTime Inc.: Sifting Through Numerous Trials For Potential Opportunities
seekingalpha.com - May 1 at 3:40 PM
prnewswire.com logoAsterias Biotherapeutics Announces Data Monitoring Committee Unanimously Recommends Continuation of SCiStar ... - PR Newswire (press release)
www.prnewswire.com - April 27 at 4:06 PM
streetinsider.com logoAsterias Biotherapeutics (AST) Reports Publication of Positive Phase 2 Data on AST-VAC1 to Treat AML - StreetInsider.com
www.streetinsider.com - April 27 at 4:06 PM
rttnews.com logoAKBA Jumps On Otsuka Deal, MNOV Abuzz, CAPR Counting On HOPE...
www.rttnews.com - April 26 at 9:49 AM
reuters.com logoBRIEF-Asterias publishes positive Phase 2 data on AST-VAC1 for the treatment of acute myeloid leukemia
www.reuters.com - April 26 at 9:49 AM
finance.yahoo.com logoAsterias Announces Publication of Positive Phase 2 Data on AST-VAC1 for the Treatment of Acute Myeloid Leukemia (AML) in 'Cancer'
finance.yahoo.com - April 26 at 9:49 AM
streetinsider.com logoAsterias Biotherapeutics (AST) Says DMC Unanimously Recommends Continuation of SCiStar Phase 1/2a Trial of AST ... - StreetInsider.com
www.streetinsider.com - April 25 at 3:38 PM
finance.yahoo.com logoAsterias Biotherapeutics Announces Data Monitoring Committee Unanimously Recommends Continuation of SCiStar …
finance.yahoo.com - April 25 at 11:21 AM
finance.yahoo.com logoImplied Volatility Surging for Asterias Biotherapeutics (AST) Stock Options
finance.yahoo.com - April 24 at 10:32 AM
finance.yahoo.com logoETFs with exposure to Asterias Biotherapeutics, Inc. : April 17, 2017
finance.yahoo.com - April 17 at 3:37 PM
finance.yahoo.com logoETFs with exposure to Asterias Biotherapeutics, Inc. : April 5, 2017
finance.yahoo.com - April 7 at 8:08 AM
finance.yahoo.com logoASTERIAS BIOTHERAPEUTICS, INC. Financials
finance.yahoo.com - April 1 at 3:44 PM
prnewswire.com logoAsterias Biotherapeutics Reports Fourth Quarter and Full Year 2016 Financial Results and Highlights Recent ... - PR Newswire (press release)
www.prnewswire.com - March 29 at 12:54 PM
us.rd.yahoo.com logoAsterias Biotherapeutics Reports Fourth Quarter and Full Year 2016 Financial Results and Highlights Recent Development Progress
us.rd.yahoo.com - March 28 at 8:40 PM
businesswire.com logoKey BioTime Patents Upheld by European Patent Office
www.businesswire.com - March 28 at 10:56 AM
biz.yahoo.com logoQ4 2016 Asterias Biotherapeutics Inc Earnings Release - After Market Close
biz.yahoo.com - March 28 at 10:56 AM
americanbankingnews.com logoAsterias Biotherapeutics Inc (AST) Stock Rating Upgraded by Zacks Investment Research
www.americanbankingnews.com - March 27 at 8:35 AM
americanbankingnews.com logoZacks Investment Research Upgrades Asterias Biotherapeutics Inc (AST) to "Buy"
www.americanbankingnews.com - March 21 at 5:01 PM
finance.yahoo.com logoUpdate on Full Six-Patient Cohort Confirms Patients with Complete Paralysis Can Experience Meaningful …
finance.yahoo.com - March 21 at 4:02 PM
reuters.com logoBRIEF-Asterias Biotherapeutics trial results continue to indicate positive safety profile for AST-OPC1
www.reuters.com - March 21 at 4:02 PM
us.rd.yahoo.com logoUpdate on Full Six-Patient Cohort Confirms Patients with Complete Paralysis Can Experience Meaningful Recovery of Function by Six Months Following AST-OPC1 Treatment
us.rd.yahoo.com - March 21 at 4:02 PM
streetinsider.com logoAsterias Biotherapeutics (AST) Announces Update on AST-OPC1 Treatment of Patients with Complete Paralysis - StreetInsider.com
www.streetinsider.com - March 21 at 12:34 PM
finance.yahoo.com logoAsterias Biotherapeutics to Report Fourth Quarter and Full Year Results on March 28, 2017
finance.yahoo.com - March 7 at 8:43 AM
investopedia.com logoBioTime Reports $56M Non-Cash Gain On Deconsolidation
www.investopedia.com - February 22 at 11:21 AM
streetinsider.com logoBioTime (BTX) Reports Deconsolidation of OncoCyte Inc.'s Financial Statements
www.streetinsider.com - February 21 at 3:57 PM
us.rd.yahoo.com logoAsterias Biotherapeutics Extends the Expiration Date of Certain Warrants and Provides Update on Cash Position
us.rd.yahoo.com - February 5 at 1:48 AM
reuters.com logoBRIEF-Asterias Biotherapeutics extends expiration date of certain warrants - Reuters
www.reuters.com - February 3 at 8:52 PM
finance.yahoo.com logoAsterias Biotherapeutics Extends the Expiration Date of Certain Warrants and Provides Update on Cash Position - Yahoo Finance
finance.yahoo.com - February 3 at 3:50 PM
streetinsider.com logoAsterias Bio (AST) Announces Efficacy Results at 6-months and 9-months Following Treatment with AST-OPC1 in Patients with Complete Cervical SCI
www.streetinsider.com - January 24 at 4:06 PM
finance.yahoo.com logoAsterias Announces Additional Motor Function Improvement at 6-months and 9-months Following Treatment …
finance.yahoo.com - January 24 at 4:06 PM
reuters.com logoBRIEF-Asterias Biotherapeutics reports positive efficacy results from company's ongoing scistar phase 1/2a clinical trial
www.reuters.com - January 24 at 4:06 PM
us.rd.yahoo.com logoAsterias Announces Additional Motor Function Improvement at 6-months and 9-months Following Treatment with AST-OPC1 in Patients with Complete Cervical Spinal Cord Injuries
us.rd.yahoo.com - January 24 at 4:06 PM
us.rd.yahoo.com logo7:12 am Asterias Biotherapeutics announces 'positive' efficacy results from its SCiStar Phase 1/2a clinical trial that showed additional motor function improvement at 6 to 9 months; expects to report 12-month data during 3Q17
us.rd.yahoo.com - January 24 at 4:06 PM
seekingalpha.com logoConnecting The Dots On Asterias Biotherapeutics...
seekingalpha.com - January 23 at 8:44 PM
thestreet.com logoNoteworthy Wednesday Option Activity: AST, KITE, TDOC
www.thestreet.com - January 18 at 4:17 PM
finance.yahoo.com logoAsterias Announces Conference Call to Discuss 6-month Efficacy Data from AST-OPC1 SCiStar Study
finance.yahoo.com - January 18 at 4:17 PM
prnewswire.com logoAsterias Announces Successful Commencement of Operations at ... - PR Newswire (press release)
www.prnewswire.com - January 9 at 4:38 PM
finance.yahoo.com logoAsterias Announces Successful Commencement of Operations at New GMP Manufacturing Facility for AST-OPC1
finance.yahoo.com - January 9 at 4:38 PM

Social

This page was last updated on 5/25/2017 by MarketBeat.com Staff